European Pharmaceutical Review
AUGUST 23, 2022
PTSD is estimated to affect some six percent of the US population, according to the US Department of Veterans Affairs. Many people have PTSD, but there [are] few effective pharmacologic treatments and limited drug development for PTSD,” commented Gradus.
Putting Patients First Blog
SEPTEMBER 30, 2024
The goal of the rare pediatric disease PRV program is to incentivize drug development for rare pediatric diseases. Extension of Priority Review Vouchers FDA Priority Review Vouchers (PRVs) for rare pediatric diseases were extended through December 20, 2024.The This bill now heads to President Biden’s desk to be signed into law.
Expert insights. Personalized for you.
94 
Let's personalize your content